Natera Inc.

Natera Inc., doing business as Natera, delivers specialized genetic and molecular diagnostic testing services to the Department of Veterans Affairs as a prime contractor operating under full-and-open (non-set-aside) competitive procedures. The company competes exclusively in the federal market without set-aside certification; all 14 awards in the source data are prime contracts and indefinite delivery contracts with no sub-award footprint.

Natera's federal capability portfolio centers on cell-free DNA analysis and advanced genomic testing for oncology and precision medicine. The company's core service lines include minimal residual disease (MRD) testing using proprietary Signatera assay technology to detect circulating tumor DNA in patient blood samples post-treatment; next-generation sequencing and peripheral blood ctDNA testing for cancer research; tumor whole exome sequencing paired with circulating tumor DNA assays; and kidney disease genetic panel testing analyzing over 380 genes across three service lines (Kidney Gene Panel Testing, Kidney Transplant Assessment, and Molecular Residual Disease Assay). Representative work includes a $6.72 million indefinite delivery contract from VA Headquarters for minimal residual disease testing services, a $550 thousand purchase order from Veterans Integrated Service Network 16 for three specialized genetic tests (Renasight, Prospera, and Signatera) delivered by a CLIA-certified and CAP-accredited reference laboratory, and a $328.3 thousand purchase order from VISN 17 for tumor whole exome sequencing and peripheral blood ctDNA testing supporting esophageal cancer research. All services are performed domestically and meet CLIA, CAP, The Joint Commission, HIPAA, and OSHA compliance requirements, with performance locations in Austin, Texas (Natera's headquarters) and Indianapolis, Indiana.

Customer concentration is entirely within the Veterans Affairs enterprise. The Department of Veterans Affairs accounts for 100% of awards across all five customer entities in the active portfolio. VA Headquarters dominates both award count and dollar share with six awards valued at $8.2 million combined potential value, primarily the three single-award indefinite delivery contracts ($6.72 million, $300 thousand, and $147.08 thousand ceilings) from which task orders flow. VISN 10 places the second-largest volume at five awards but only $413 thousand combined potential value, reflecting smaller individual purchase orders and delivery orders; VISN 16, VISN 17, and VISN 19 account for the remaining single or individual awards at $550 thousand, $328 thousand, and $79 thousand respectively.

Activity has accelerated in 2025 and 2026 after a flat 2022–2024 period, with five awards in 2025 and three awards in 2026 (most recent award July 13, 2026). The company holds two active parent IDIQs under 36C10G22D0036 (minimal residual disease testing, four task orders, $1.2 million combined potential value) and 36C24E25D0014 (next-generation sequencing and ctDNA testing, two task orders, $109 thousand combined potential value). Only $231 thousand in combined potential value reaches ultimate completion within the next twenty-four months, limiting near-term recompete exposure. Across all fourteen awards, Natera has obligated $1.8 million against a combined $9.6 million potential value (19% obligation rate), indicating substantial remaining capacity on active vehicles. The company's federal footprint is narrowly specialized: all awards fall under NAICS 621511 (Medical Laboratories) and PSC Q301 (Reference Laboratory Testing).